Skip to main content
Terug
Watch Compare

FILANA THERAPEUTICS, INC.

Datakwaliteit: 83%
FLNA
Nasdaq Manufacturing Chemicals
€ 1,64
▼ € 0,08 (-4,65%)
Marktkapitalisatie: 83,09 M
Prijs
€ 1,72
Marktkapitalisatie
83,09 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -32,83 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-107,32%
Onder sectorgemiddelde (-53,34%)
ROIC-88,79%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio2,27
Interest CoverageN/A

Waardering

PE (TTM)
-0,91
Boven sectorgemiddelde (-1,47)
P/B Ratio1,02
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,9 -1,5
P/B 1,0 1,6
ROE % -107,3 -53,3
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

1 analist
Buy
Huidig
€ 1,64
+387.8%
Koersdoel
€ 8,00
€ 8,00
€ 8,00
€ 8,00
Vooruitzicht
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 — 0,0 —
FY2026 -€ 1,02
-€ 1,02 – -€ 1,02
 0,0 1

Winstverassingen

Laatste 3 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,30 -€ 0,26 +13,3%
Q32025 -€ 0,27 -€ 0,22 +18,5%
Q22025 N/A -€ 0,92 —

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -90,97 M
ROE -107,32% ROA -68,63%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -32,83 M
ROIC -88,79% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,27
Interest Coverage N/A Asset Turnover N/A
Working Capital 60,86 M Tangible Book Value 81,57 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,91 Forward P/E N/A
P/B Ratio 1,02 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -39,52%
Market Cap 83,09 M Enterprise Value -22,99 M
Per Share
EPS (Diluted TTM) -1,88 Revenue / Share N/A
FCF / Share -0,68 OCF / Share -0,67
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 36,09%
SBC-Adj. FCF -52,65 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -90,97 M -24,34 M -97,22 M -76,25 M -32,39 M
EPS (Diluted) -1,88 -1,46 — — —
Gross Profit — — — — —
Operating Income -95,39 M -141,45 M -105,96 M -80,02 M -32,87 M
EBITDA — — — — —
R&D Expenses 26,59 M 69,64 M 89,42 M — —
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax 0,0 0,0 — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 118,36 M 157,53 M 151,66 M 234,83 M 266,78 M
Total Liabilities 43,95 M 11,83 M 14,20 M 7,30 M 12,87 M
Shareholders' Equity 74,40 M 145,70 M 137,47 M 227,54 M 253,92 M
Total Debt — — — — —
Cash & Equivalents 95,50 M 128,57 M 121,14 M 201,02 M 233,44 M
Current Assets 97,71 M 136,53 M 129,63 M 211,23 M 244,48 M
Current Liabilities 43,83 M 11,75 M 14,20 M 7,06 M 12,53 M